MA55809B1 - Formulations d'anticorps anti-il-6 - Google Patents

Formulations d'anticorps anti-il-6

Info

Publication number
MA55809B1
MA55809B1 MA55809A MA55809A MA55809B1 MA 55809 B1 MA55809 B1 MA 55809B1 MA 55809 A MA55809 A MA 55809A MA 55809 A MA55809 A MA 55809A MA 55809 B1 MA55809 B1 MA 55809B1
Authority
MA
Morocco
Prior art keywords
antibody formulation
antibody formulations
disorders
oxidation
treating
Prior art date
Application number
MA55809A
Other languages
English (en)
Other versions
MA55809A (fr
Inventor
Gaozhong Zhu
Zahra Shahrokh
Mark Melville
Madhav N. DEVALARAJA
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of MA55809A publication Critical patent/MA55809A/fr
Publication of MA55809B1 publication Critical patent/MA55809B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations d'anticorps anti-IL-6 aqueuses stables qui ont un niveau de formation d'agrégat et d'oxydation réduit. Les formulations d'anticorps anti-IL-6 sont appropriées pour traiter des maladies et des troubles médiés par IL-6.
MA55809A 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6 MA55809B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962841662P 2019-05-01 2019-05-01
EP19181345 2019-06-19
EP20728590.9A EP3962942B1 (fr) 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6
PCT/US2020/030865 WO2020223565A1 (fr) 2019-05-01 2020-04-30 Formulation d'anticorps anti-il-6

Publications (2)

Publication Number Publication Date
MA55809A MA55809A (fr) 2022-03-09
MA55809B1 true MA55809B1 (fr) 2025-12-31

Family

ID=70857238

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55809A MA55809B1 (fr) 2019-05-01 2020-04-30 Formulations d'anticorps anti-il-6

Country Status (8)

Country Link
EP (3) EP4591885A3 (fr)
JP (3) JP7701273B2 (fr)
ES (1) ES3055418T3 (fr)
HR (1) HRP20251529T1 (fr)
MA (1) MA55809B1 (fr)
PL (1) PL3962942T3 (fr)
RS (1) RS67540B1 (fr)
WO (1) WO2020223565A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6808194A (en) 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
ES2436206T3 (es) 2001-11-14 2013-12-27 Janssen Biotech, Inc. Anticuerpos anti il-6, composiciones, métodos y usos
CA2496523A1 (fr) 2002-08-30 2004-03-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticorps d'interleukine-6 antihumaine de type humain et fragment de l'anticorps
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
JP2012516158A (ja) 2009-01-29 2012-07-19 メディミューン，エルエルシー 延長したインビボ半減期を有するヒト抗ｉｌ−６抗体ならびに腫瘍学、自己免疫疾患、および炎症性疾患の治療におけるそれらの使用
EP2399604A1 (fr) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN106421782A (zh) 2012-10-25 2017-02-22 米迪缪尼有限公司 稳定的低粘度抗体配制品
KR102709681B1 (ko) 2015-07-31 2024-09-26 메디뮨 리미티드 헵시딘 매개 장애의 치료 방법
CA3012350A1 (fr) 2016-02-23 2017-08-31 Sesen Bio, Inc. Formulations d'antagonistes d'il-6 et leurs utilisations
WO2018144773A1 (fr) 2017-02-01 2018-08-09 Yale University Traitement de la résistance aux diurétiques
JP7395479B2 (ja) 2018-01-05 2023-12-11 ノヴォ ノルディスク アー／エス 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法

Also Published As

Publication number Publication date
JP7701273B2 (ja) 2025-07-01
JP2025166156A (ja) 2025-11-05
ES3055418T3 (en) 2026-02-11
EP4591885A3 (fr) 2025-11-19
JP7755766B2 (ja) 2025-10-16
RS67540B1 (sr) 2026-01-30
EP4591885A2 (fr) 2025-07-30
PL3962942T3 (pl) 2026-02-16
MA55809A (fr) 2022-03-09
WO2020223565A1 (fr) 2020-11-05
EP3962942C0 (fr) 2025-10-22
EP4631523A3 (fr) 2025-12-31
EP3962942B1 (fr) 2025-10-22
JP2022531331A (ja) 2022-07-06
HRP20251529T1 (hr) 2026-01-16
EP4631523A2 (fr) 2025-10-15
JP2025114623A (ja) 2025-08-05
EP3962942A1 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020551716A1 (en) Anti-ror antibody constructs
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
JOP20230234A1 (ar) أجسام مضادة لـ il-2r مؤازرة وطرق استخدامها
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
WO2019209965A3 (fr) Protéines de fusion de l'interleukine 12, et compositions et procédés thérapeutiques associés
MX2023002507A (es) Inhibidores de cd73.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
EP4378536A3 (fr) Inhibiteurs peptidiques oraux du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies intestinales inflammatoires
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
JOP20200157A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
WO2020171727A3 (fr) Compositions mucoadhésives et leurs utilisations
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2020123773A3 (fr) Anellosomes pour l'administration de modalités thérapeutiques sécrétées
ZA202006264B (en) Stable formulations of therapeutic antibody
EA201791937A1 (ru) Противовоспалительные полипептиды
MA55809B1 (fr) Formulations d'anticorps anti-il-6
PH12022550277A1 (en) Biopharmacuetical compositions and related methods
MX2024001374A (es) Anticuerpo anti-il-15 o fragmento de union a antigeno del mismo, para usarse en el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
MX2021007853A (es) Compuestos de tienopiridinona.